| Old Articles: <Older 8701-8710 Newer> |
|---|
 |
Chemistry World
October 23, 2013
Sarah Houlton |
Pharma manufacturing woes dog industry Many problems arise from quality control failures, according to Nicholson Price from Harvard Law School's Petrie-Flom center for health law policy, biotechnology and bioethics, this is not the only problem -- regulatory constraints can prevent process improvements being made.   |
Information Today
October 22, 2013 |
Wiley and The Cochrane Collaboration Develop Cochrane Learning Wiley and The Cochrane Collaboration recently launched Cochrane Learning, a professional development resource for the healthcare industry. |
Chemistry World
October 21, 2013
Phillip Broadwith |
Counterfeit anxiety pills seized in Switzerland Swiss authorities have intercepted a large shipment of counterfeit tablets in transit between China and Egypt. The four crates contained over a million fake versions of Pfizer's Xanax (alprazolam) pills, which have now been destroyed. |
Chemistry World
October 15, 2013
Emily James |
Roche backs biologic boom The world's largest biotech company, Roche, has announced it will invest 800 million Swiss francs into manufacturing biological medicines over the next five years. |
Chemistry World
October 15, 2013
Dinsa Sachan |
Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed. |
Chemistry World
October 14, 2013
Phillip Broadwith |
5000 jobs to be cut at Teva Israeli generics heavyweight Teva is accelerating its previously announced costcutting drive. |
Chemistry World
October 9, 2013
Phillip Broadwith |
GSK to apply for malaria vaccine approval Preliminary results from the first ever Phase III clinical trial of a malaria vaccine show that it can reduce malaria infections in vaccinated children over 18 months. |
Chemistry World
October 4, 2013
Phillip Broadwith |
Lundbeck cuts jobs in Europe, but expands in US Danish drugmaker Lundbeck is cutting 180-200 jobs in Europe as part of its ongoing restructuring program. However, the company is currently in the process of expanding its staff in the US. |
Chemistry World
October 4, 2013
Andy Extance |
Amid huge cuts, Merck vows research focus US-based drug giant Merck & Co will cut 8,500 more jobs as it seeks to cut costs by $2.5 billion |
Chemistry World
October 2, 2013
Phillip Broadwith |
Aspen acquires anticoagulant brands South African generics manufacturer Aspen has bought two heparin-derived thrombosis drugs from GlaxoSmithKline. |
| <Older 8701-8710 Newer> Return to current articles. |
